Tags

Type your tag names separated by a space and hit enter

Introductory remarks: Catechol-O-methyltransferase inhibition--an innovative approach to enhance L-dopa therapy in Parkinson's disease with dual enzyme inhibition.
Int Rev Neurobiol. 2010; 95:1-5.IR

Abstract

Catechol-O-methyltransferase (COMT) enzyme and its inhibition have been closely related to the treatment of Parkinson's disease (PD) patients with motor fluctuations needing enhancement of their levodopa (L-dopa) therapy (L-dopa/dopa decarboxylase inhibitor), this indication being so far the only clinical application of COMT inhibitors. L-dopa treatment has remained the most effective therapy for PD, but its further development has been quite a challenge mainly due to the effective metabolism of L-dopa in the human body by multiple pathways, decarboxylation and O-methylation being the two most important of them. The introduction of clinically effective and safe COMT inhibitors has greatly increased the usefulness of L-dopa therapy, but how to utilize the full potential of L-dopa is still unsolved leaving a need for more potent COMT inhibitors.

Authors+Show Affiliations

Orion Corporation, Orion Pharma, Research and Development, Research Center, Espoo, Finland.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

21095456

Citation

Nissinen, Erkki. "Introductory Remarks: Catechol-O-methyltransferase Inhibition--an Innovative Approach to Enhance L-dopa Therapy in Parkinson's Disease With Dual Enzyme Inhibition." International Review of Neurobiology, vol. 95, 2010, pp. 1-5.
Nissinen E. Introductory remarks: Catechol-O-methyltransferase inhibition--an innovative approach to enhance L-dopa therapy in Parkinson's disease with dual enzyme inhibition. Int Rev Neurobiol. 2010;95:1-5.
Nissinen, E. (2010). Introductory remarks: Catechol-O-methyltransferase inhibition--an innovative approach to enhance L-dopa therapy in Parkinson's disease with dual enzyme inhibition. International Review of Neurobiology, 95, 1-5. https://doi.org/10.1016/B978-0-12-381326-8.00001-6
Nissinen E. Introductory Remarks: Catechol-O-methyltransferase Inhibition--an Innovative Approach to Enhance L-dopa Therapy in Parkinson's Disease With Dual Enzyme Inhibition. Int Rev Neurobiol. 2010;95:1-5. PubMed PMID: 21095456.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Introductory remarks: Catechol-O-methyltransferase inhibition--an innovative approach to enhance L-dopa therapy in Parkinson's disease with dual enzyme inhibition. A1 - Nissinen,Erkki, PY - 2010/11/25/entrez PY - 2010/11/26/pubmed PY - 2011/3/8/medline SP - 1 EP - 5 JF - International review of neurobiology JO - Int Rev Neurobiol VL - 95 N2 - Catechol-O-methyltransferase (COMT) enzyme and its inhibition have been closely related to the treatment of Parkinson's disease (PD) patients with motor fluctuations needing enhancement of their levodopa (L-dopa) therapy (L-dopa/dopa decarboxylase inhibitor), this indication being so far the only clinical application of COMT inhibitors. L-dopa treatment has remained the most effective therapy for PD, but its further development has been quite a challenge mainly due to the effective metabolism of L-dopa in the human body by multiple pathways, decarboxylation and O-methylation being the two most important of them. The introduction of clinically effective and safe COMT inhibitors has greatly increased the usefulness of L-dopa therapy, but how to utilize the full potential of L-dopa is still unsolved leaving a need for more potent COMT inhibitors. SN - 2162-5514 UR - https://www.unboundmedicine.com/medline/citation/21095456/Introductory_remarks:_Catechol_O_methyltransferase_inhibition__an_innovative_approach_to_enhance_L_dopa_therapy_in_Parkinson's_disease_with_dual_enzyme_inhibition_ L2 - https://linkinghub.elsevier.com/retrieve/pii/B978-0-12-381326-8.00001-6 DB - PRIME DP - Unbound Medicine ER -